Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Tallman

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Cytometry. Part B, Clinical Cytometry|April 27, 2004
A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypesE Paietta, O Goloubeva, D Neuberg, et al.
British Journal of Haematology|March 6, 1998
Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology GroupE Paietta, J Andersen, J Yunis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experienceM S Tallman, R Gray, J M Bennett, et al.
Journal of Thrombosis and Haemostasis : JTH|August 12, 2004
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemiaM S Tallman, P Lefèbvre, R M Baine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposideM S Tallman, F R Appelbaum, D Amos, et al.
Bone Marrow Transplantation|May 16, 2003
Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?M Y Ali, Y Oyama, J Monreal, et al.
Blood|August 15, 1995
Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acidR E Gallagher, Y P Li, S Rao, et al.
Blood|August 8, 1998
Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapyW Ding, Y P Li, L M Nobile, et al.
Leukemia|July 30, 2003
Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trialsE Paietta, D Neuberg, J M Bennett, et al.
Cancer|December 12, 1997
Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experienceJ M Bennett, M L Young, J W Andersen, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Cytometry. Part B, Clinical Cytometry|April 27, 2004
A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypesE Paietta, O Goloubeva, D Neuberg, et al.
British Journal of Haematology|March 6, 1998
Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology GroupE Paietta, J Andersen, J Yunis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experienceM S Tallman, R Gray, J M Bennett, et al.
Journal of Thrombosis and Haemostasis : JTH|August 12, 2004
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemiaM S Tallman, P Lefèbvre, R M Baine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposideM S Tallman, F R Appelbaum, D Amos, et al.
Bone Marrow Transplantation|May 16, 2003
Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?M Y Ali, Y Oyama, J Monreal, et al.
Blood|August 15, 1995
Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acidR E Gallagher, Y P Li, S Rao, et al.
Blood|August 8, 1998
Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapyW Ding, Y P Li, L M Nobile, et al.
Leukemia|July 30, 2003
Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trialsE Paietta, D Neuberg, J M Bennett, et al.
Cancer|December 12, 1997
Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experienceJ M Bennett, M L Young, J W Andersen, et al.
Pageof 10